Abstract
A protective effect of nicotine against glutamate-induced neurotoxicity has previously been reported in cultured striatal and cortical neurons. The aim of this study was to investigate whether nicotine also inhibits glutamate-evoked arachidonic acid release from cultured striatal neurons. (−)-Nicotine selectively inhibited the release of [3H]-arachidonic acid induced by the joint stimulation of α-amino-3-isoxazol-5-propionic acid and metabotropic receptors, whereas the response evoked by the sole activation of N-methyl-d-aspartate receptors remained unchanged. The inhibitory effect of (−)-nicotine was not mediated by nicotinic receptors because it was neither reproduced by acetylcholine (in the presence of atropine) or 1,1-dimethyl-4-phenyl piperazinium, nor reversed by dihydro-β-erythroidine or hexamethonium, two central nicotinic receptor antagonists. (−)-Nicotine, which induced rapidly desensitizing inward currents in 17% of striatal neurons, did not alter the α-amino-3-isoxazol-5-propionic acid-evoked currents. Moreover, (−)-nicotine did not inhibit the accumulation of inositol phosphate derivatives induced by agonists of glutamate metabotropic receptors. In fact, using the fluorogenic phospholipase A2 substrate 1,2-bis-(1-pyrenedecanoyl)-sn-glycero-3-phosphocholine, (−)-nicotine was found to inhibit both particulate and soluble phospholipase A2 activities from striatal neurons. Therefore, (−)-nicotine can modulate a neuronal response (arachidonic acid release) evoked by glutamate but this process is not involved in the neuroprotective effect of the drug on glutamate-induced neurotoxicity.
Footnotes
-
Send reprint requests to: Dr. Philippe Marin, INSERM U114, Chaire de Neuropharmacologie, Collège de France, 11, Place Marcelin Berthelot, 75231 Paris Cedex 05, France.
-
↵1 This research was supported by grants from Institut National de la Santé et de la Recherche Médicale (INSERM), Direction des Recherches, Etudes et Techniques (DRET, Contract 94/158), Rhône Poulenc Rorer and Philip Morris Europe.
- Abbreviations:
- trans-ACPD
- (1S-3R)-1-aminocyclopentane-1,3-dicarboxylic acid
- AMPA
- α-amino-3-isoxazol-5-propionic acid
- DHBE
- dihydro-β-erythroidine
- DMPP
- 1,1-dimethyl-4-phenyl piperazinium
- GPT
- glutamate-pyruvate transaminase
- MK-801
- (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine hydrogen maleate
- NMDA
- N-methyl-d-aspartate
- p-BPB
- p-bromophenacyl bromide
- PLA2
- phospholipase A2
- PPC
- 1,2-bis-(1-pyrenedecanoyl)-sn-glycero-3-phosphocholine
- Received June 24, 1996.
- Accepted November 18, 1996.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|